Primary biliary cholangitis (PBC) is a rare chronic autoimmune cholangiopathy that mainly affects middle-aged women, ...
In chronic hepatitis B virus (HBV) infection, the central debate remains whom and when to treat. The 2025 European Association for the Study of the Liver (EASL) Clinical Practice Guidelines (CPGs)1 ...
Background Post-infection disorders of gut-brain interaction (PI-DGBI) are a subset of chronic gastrointestinal disorders triggered by acute infectious gastroenteritis. These conditions impose a ...
2 Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK 3 Institute of Applied Health Research, University of Birmingham, Birmingham, UK Correspondence to Dr Palak J ...
Correspondence to Hong-Yang Wang and Jin Ding, The International Cooperation Laboratory on Signal Transduction, Shanghai Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, 225 ...
Chronic hepatitis D (CHD) is the most severe form of viral hepatitis, carrying a greater risk of developing cirrhosis and its complications. For decades, pegylated interferon alpha (PegIFN-α) has ...
Objective Faecal microbiota transplantation (FMT) has variable efficacy in treating UC. Recently, oral lyophilised FMT was found to induce remission in patients with UC, with one donor having 100% ...
Objective Acinar cells display plasticity in vitro and in vivo and can activate a variety of differentiation programmes that may contribute to pancreatic diseases. The aims were to determine: (1) the ...
Objective Intestinal barrier loss is a Crohn’s disease (CD) risk factor. This may be related to increased expression and enzymatic activation of myosin light chain kinase 1 (MLCK1), which increases ...
Correspondence to Dr James R Goldenring, Epithelial Biology Center and Section of Surgical Sciences, Vanderbilt University Medical Center, 10435-G MRB IV, 2213 Garland Avenue, Nashville, TN 37232, USA ...
Background Liver failure is the most critical outcome of end-stage liver diseases, with a 28-day mortality rate in the acute phase ranging from 25% to 84% due to a narrow therapeutic window. Liver ...
Objective Gastric cancer (GC) ranks fifth in incidence and fourth for mortality worldwide. The response to immune checkpoint blockade (ICB) therapy in GC is heterogeneous due to tumour-intrinsic and ...